Chemotherapy in Gynecologic Oncology

On this page

Chemotherapy in Gynecologic Oncology - Chemo Agent Arsenal

  • Platinum Agents: (Cisplatin, Carboplatin)
    • Mechanism: Cross-link DNA; non-cell cycle specific.
    • Backbone for ovarian, cervical, endometrial cancers.
  • Taxanes: (Paclitaxel, Docetaxel)
    • Mechanism: Stabilize microtubules; M-phase specific.
    • Often combined with platinums.
  • Alkylating Agents: (Cyclophosphamide, Ifosfamide)
    • Mechanism: Alkylate DNA; non-cell cycle specific.
  • Antimetabolites: (Methotrexate, Gemcitabine)
    • Mechanism: Interfere with DNA/RNA synthesis; S-phase specific.
  • Topoisomerase Inhibitors: (Topotecan, Etoposide)
    • Mechanism: Inhibit DNA unwinding/replication.
  • Antitumor Antibiotics: (Doxorubicin, Bleomycin)
    • Mechanism: Intercalate DNA, generate free radicals.

⭐ Platinum resistance in ovarian cancer is defined as disease progression within 6 months of completing platinum-based chemotherapy.

Chemotherapy in Gynecologic Oncology - Targeted Smart Strikes

  • PARP Inhibitors (Olaparib, Niraparib, Rucaparib)
    • Mechanism: Synthetic lethality in BRCA-mutated (BRCAm) / Homologous Recombination Deficiency (HRD) cells; inhibits DNA repair.
    • Uses: Ovarian Cancer (Ca) (maintenance in Platinum-Sensitive Recurrent Ovarian Cancer [PSROC], BRCAm).
    • Key Side Effects (SE): Nausea, fatigue, anemia.
  • Anti-angiogenic Therapy (Bevacizumab)
    • Mechanism: Anti-VEGF-A monoclonal antibody (mAb); inhibits tumor angiogenesis.
    • Uses: Ovarian Ca (front-line with chemotherapy, recurrent); Cervical Ca (persistent/recurrent/metastatic).
    • ⚠️ Key Risks: Hypertension (HTN), proteinuria, bleeding, GI perforation, thrombosis.
  • Immune Checkpoint Inhibitors (Pembrolizumab, Dostarlimab)
    • Mechanism: PD-1/PD-L1 blockade; restores T-cell anti-tumor activity.
    • Uses: Microsatellite Instability-High (MSI-H)/deficient Mismatch Repair (dMMR) Endometrial Ca; PD-L1 positive Cervical Ca.

⭐ Olaparib (a PARP inhibitor) significantly improves Progression-Free Survival (PFS) as maintenance therapy in patients with BRCA-mutated, platinum-sensitive recurrent ovarian cancer (PSROC).

Chemotherapy in Gynecologic Oncology - Cancer Battle Plans

  • Core Principles:
    • Neoadjuvant: Shrink tumor pre-surgery/RT (e.g., bulky cervical).
    • Adjuvant: Post-definitive treatment (surgery/RT) to target micrometastases. Common in Epithelial Ovarian Cancer (EOC).
    • Palliative: Advanced/recurrent disease; goal is symptom control & Quality of Life (QoL).
  • Key Drug Classes & Examples:
    • Platinum: Cisplatin (nephrotoxic, ototoxic), Carboplatin (myelosuppressive; Calvert formula: Dose = $Target AUC \times (GFR+25)$)
    • Taxanes: Paclitaxel (neuropathy, hypersensitivity), Docetaxel
    • Anthracyclines: Doxorubicin (cardiotoxic; for sarcomas, recurrent ovarian/endometrial)
    • Topoisomerase Inhibitors: Topotecan (2nd line ovarian/cervical)
    • Targeted Therapy:
      • Bevacizumab (Anti-VEGF; hypertension, VTE risk)
      • PARP Inhibitors (Olaparib, Niraparib for BRCAm/HRD+ EOC; GI toxicity, fatigue)
Loading diagram…

⭐ PARP inhibitors (e.g., Olaparib) significantly improve Progression-Free Survival (PFS) in BRCA-mutated ovarian cancer as maintenance therapy.

  • 📌 Mnemonic for common Ovarian chemo: "CarboTax" (Carboplatin + Paclitaxel).

Chemotherapy in Gynecologic Oncology - Toxicity Damage Control

  • General: Dose modification, supportive care.
  • Myelosuppression:
    • Neutropenia: G-CSF. Febrile Neutropenia (FN): ANC < 500/µL + fever.
    • Anemia: ESAs, transfusions.
    • Thrombocytopenia: Transfuse if platelets < 10-20k/µL or bleeding.
  • Chemotherapy-Induced Nausea & Vomiting (CINV):
    • Prophylaxis: 5-HT3 antags (Ondansetron), NK1-R antags (Aprepitant), Dexamethasone.
  • Agent-Specific Toxicities & Management:
    • Cisplatin: Nephrotoxicity (hydration, Amifostine), Ototoxicity, Neurotoxicity.
    • Paclitaxel: Neurotoxicity, Myelosuppression. Premedicate for hypersensitivity.
    • Doxorubicin: Cardiotoxicity (Dexrazoxane, LVEF monitoring; max dose 450-550 mg/m²).
    • Cyclophosphamide/Ifosfamide: Hemorrhagic cystitis (MESNA, hydration).
    • Methotrexate: Myelosuppression, Mucositis (Leucovorin rescue).

⭐ Cisplatin-induced nephrotoxicity is dose-limiting; manage with hydration & Amifostine.

High‑Yield Points - ⚡ Biggest Takeaways

  • Platinum agents (Cisplatin, Carboplatin) are cornerstone for epithelial ovarian cancer.
  • Paclitaxel + Platinum is a standard combination for ovarian, endometrial, and cervical cancers.
  • BEP regimen (Bleomycin, Etoposide, Cisplatin) is key for ovarian germ cell tumors.
  • Methotrexate for low-risk GTN; EMA-CO for high-risk GTN.
  • PARP inhibitors (e.g., Olaparib) are crucial for BRCA-mutated ovarian cancer.
  • Bevacizumab (anti-VEGF) used for advanced/recurrent ovarian and cervical cancer.
  • Key toxicities: Cisplatin (nephro/neuro/ototoxicity), Bleomycin (pulmonary fibrosis).

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Chemotherapy in Gynecologic Oncology

  1. 1. A 62-year-old man with active lung cancer has Doppler-confirmed proximal DVT. Persistent chemotherapy-induced vomiting prevents oral medication. Renal function and platelet count are normal, and there is no active bleeding. Which anticoagulant is preferred for initial treatment?

    • A. LMWH
    • B. Apixaban
    • C. Warfarin
    • D. Rivaroxaban
    Show answer

    Answer: A. LMWH

    Low-molecular-weight heparin is preferred here because it provides therapeutic parenteral anticoagulation while vomiting prevents oral treatment. Apixaban is an accepted option for selected patients with cancer-associated thrombosis but cannot be reliably administered orally in this patient. Warfarin also requires oral administration and has additional interaction and monitoring disadvantages during cancer treatment. Rivaroxaban is likewise an accepted option in suitable patients, but the stated inability to retain oral medication makes it inappropriate at this stage.

  2. 2. Which antineoplastic drug inhibits de novo purine nucleotide synthesis?

    • A. Mitomycin C
    • B. Mercaptopurine
    • C. Actinomycin D
    • D. L-Asparaginase
    Show answer

    Answer: B. Mercaptopurine

    Mercaptopurine inhibits de novo purine nucleotide synthesis after metabolic activation. L-Asparaginase depletes asparagine and principally impairs protein synthesis. Actinomycin D intercalates into DNA and principally inhibits transcription. Mitomycin C cross-links DNA and inhibits replication, but does not act by inhibiting de novo purine synthesis.

  3. 3. Which drug is most appropriate for reducing risk of ovarian cancer in a BRCA1 positive woman not planning for children?

    • A. Levonorgestrel
    • B. Combined OCPs
    • C. Tamoxifen
    • D. GnRH agonists
    Show answer

    Answer: B. Combined OCPs

    Combined OCPs are associated with reduced ovarian-cancer risk in BRCA1 carriers, with greater protection after longer use. Tamoxifen is used for selected breast-cancer indications, not ovarian-cancer prevention. Levonorgestrel alone does not have an established equivalent preventive role in BRCA1-associated ovarian cancer. GnRH agonists are used for reversible ovarian suppression but are not established ovarian-cancer chemoprevention.

  4. 4. A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?

    • A. Amifostine
    • B. Filgrastim
    • C. Oprelvekin
    • D. Erythropoietin
    Show answer

    Answer: C. Oprelvekin

    Oprelvekin - Oprelvekin, a recombinant interleukin-11, stimulates megakaryocyte proliferation and maturation, increasing platelet production. - It is indicated after myelosuppressive chemotherapy to prevent severe thrombocytopenia and reduce the need for platelet transfusions. Erythropoietin - Erythropoietin promotes proliferation and differentiation of erythroid progenitor cells, thereby increasing red blood cell production rather than platelet production. - It is useful for chemotherapy-associated anemia and other causes of reduced erythropoiesis, but it does not treat thrombocytopenia after chemotherapy. Amifostine - Amifostine is a cytoprotective agent and free-radical scavenger that reduces some chemotherapy- and radiation-associated toxicities by protecting normal tissues. - It does not directly stimulate megakaryocyte proliferation or platelet production, so it is not the appropriate treatment for chemotherapy-induced thrombocytopenia. Filgrastim - Filgrastim is a recombinant granulocyte colony-stimulating factor that promotes proliferation and maturation of neutrophil precursors. - It is used to prevent or treat neutropenia and reduce febrile neutropenia, but it does not significantly increase platelet counts.

  5. 5. For conventional Point A-based definitive radiotherapy of cervical cancer, what approximate cumulative dose from external-beam radiotherapy plus brachytherapy is delivered to Point A, expressed as EQD2 using an α/β of 10 Gy?

    • A. 8000 rad
    • B. 4000 rad
    • C. 6000 rad
    • D. 10000 rad
    Show answer

    Answer: A. 8000 rad

    8000 rad corresponds to 80 Gy and is the closest listed value to a conventional cumulative Point A target of approximately 80–90 Gy EQD2 from external-beam radiotherapy plus brachytherapy. 10000 rad corresponds to 100 Gy and exceeds this usual cumulative target, although toxicity also depends on organ-at-risk doses and fractionation. 4000 rad corresponds to 40 Gy and is below the usual cumulative definitive target. 6000 rad corresponds to 60 Gy and is also below that target; none of these figures should be interpreted as a universal physical brachytherapy-only dose.

  6. 6. Which anticancer drug is known to inhibit spindle formation during cell division?

    • A. Methotrexate
    • B. Fluorouracil
    • C. Vincristine
    • D. Busulfan
    Show answer

    Answer: C. Vincristine

    Vincristine - Vincristine binds tubulin and prevents microtubule polymerization. - This directly inhibits mitotic spindle formation, producing metaphase arrest and eventual death of the dividing cell. Methotrexate - Methotrexate is an antifolate that inhibits dihydrofolate reductase, reducing purine and pyrimidine synthesis and thereby impairing DNA and RNA production. - Its principal effect is nucleotide depletion in rapidly dividing cells, not direct disruption of microtubules or mitotic spindle formation. Fluorouracil - Fluorouracil is an antimetabolite that primarily inhibits thymidylate synthase, impairing DNA synthesis and repair in rapidly dividing cells. - Although it can be incorporated into DNA and RNA, its mechanism does not directly prevent tubulin polymerization or spindle formation. Busulfan - Busulfan is an alkylating agent that cross-links DNA, interfering with DNA replication and transcription. - Its defining action is DNA damage, rather than direct inhibition of microtubules or mitotic spindle formation.

  7. 7. Leucovorin is used for side effect reduction in which anticancer drug?

    • A. Cisplatin
    • B. Fluorouracil
    • C. Doxorubicin
    • D. Methotrexate
    Show answer

    Answer: D. Methotrexate

    Methotrexate - Leucovorin rescue prevents severe methotrexate toxicity by supplying folinic acid, a reduced folate that bypasses the blocked dihydrofolate reductase pathway. - Because methotrexate is a folate antagonist, leucovorin restores folate-dependent cellular function and preferentially protects normal cells after methotrexate treatment. Cisplatin - Cisplatin toxicity is principally nephrotoxicity and ototoxicity, rather than folate depletion requiring leucovorin rescue. - Cisplatin adverse effects are managed with hydration, amifostine, and antiemetics; leucovorin does not reverse its platinum-mediated toxicity. Fluorouracil - Leucovorin is combined with fluorouracil to enhance thymidylate synthase inhibition and potentiate its cytotoxic effect, not to reduce fluorouracil toxicity. - The distinguishing principle is potentiation with fluorouracil versus rescue after methotrexate; fluorouracil itself can cause myelosuppression and gastrointestinal toxicity. Doxorubicin - Doxorubicin is an anthracycline associated with cardiotoxicity and myelosuppression, not folate-antagonist toxicity. - Dexrazoxane, rather than leucovorin, is used to reduce doxorubicin-related cardiotoxicity; leucovorin does not provide the relevant protective mechanism.

  8. 8. What is the mechanism of action of Bevacizumab?

    • A. Histone deacetylase inhibitor
    • B. Anti VEGF antibody
    • C. HER2 neu inhibitor
    • D. Proteasome inhibitor
    Show answer

    Answer: B. Anti VEGF antibody

    Anti VEGF antibody - Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF). - VEGF neutralization prevents formation of new tumor blood vessels (angiogenesis), limiting the vascular support required for tumor growth and metastasis. Histone deacetylase inhibitor - Histone deacetylase inhibitors alter chromatin structure and gene expression, producing cell-cycle arrest and apoptosis in susceptible cancer cells. - HDAC inhibitors inhibit histone deacetylases rather than directly neutralizing VEGF; they can also exert downstream antiangiogenic effects. HER2 neu inhibitor - HER2/neu inhibitors, such as trastuzumab, target the HER2 receptor overexpressed in some breast and gastric cancers. - They block receptor-mediated growth signaling rather than neutralizing VEGF or directly inhibiting tumor angiogenesis. Proteasome inhibitor - Proteasome inhibitors, such as bortezomib, block protein degradation, causing accumulation of ubiquitinated proteins and cancer-cell apoptosis. - This intracellular protein-processing mechanism is distinct from bevacizumab’s blockade of VEGF-mediated angiogenesis.

  9. 9. Which of the following most commonly produces osteoblastic secondaries?

    • A. Carcinoma urinary bladder
    • B. Carcinoma breast
    • C. Carcinoma lung
    • D. Carcinoma prostate
    Show answer

    Answer: D. Carcinoma prostate

    Carcinoma prostate - Prostate carcinoma has a strong predilection for bone and characteristically produces osteoblastic, bone-forming metastases. - Tumor-derived factors stimulate osteoblast activity, resulting in new bone formation; therefore, prostate carcinoma is the best answer. Carcinoma breast - Breast carcinoma commonly metastasizes to bone, but these deposits may be osteolytic, osteoblastic, or mixed rather than characteristically osteoblastic. - Because osteolytic lesions are more frequent in breast cancer, it is less likely than prostate carcinoma to produce purely osteoblastic secondaries. Carcinoma lung - Lung carcinoma commonly spreads to bone, but its metastases are predominantly osteolytic, reflecting bone destruction rather than formation. - Although some lung cancer subtypes can rarely produce osteoblastic changes, this is not the typical pattern. Carcinoma urinary bladder - Urinary bladder carcinoma can metastasize to bone, but its deposits usually produce osteolytic lesions rather than osteoblastic lesions. - Bone involvement from bladder cancer is also less common than from prostate or breast carcinoma and generally indicates advanced disease.

  10. 10. An adolescent girl with stage 1a dysgerminoma is managed by:

    • A. Chemotherapy
    • B. Bilateral salpingo-oophorectomy alone
    • C. Total abdominal hysterectomy with unilateral salpingo-oophorectomy
    • D. Unilateral salpingo-oophorectomy alone
    Show answer

    Answer: D. Unilateral salpingo-oophorectomy alone

    Unilateral salpingo-oophorectomy alone - Unilateral salpingo-oophorectomy removes the affected ovary while preserving the uterus and contralateral ovary, providing fertility-sparing treatment for localized stage 1a dysgerminoma. - Because the tumor is confined to one ovary and dysgerminoma is highly chemosensitive, complete surgery is generally sufficient without routine additional chemotherapy. Total abdominal hysterectomy with unilateral salpingo-oophorectomy - Total abdominal hysterectomy with unilateral salpingo-oophorectomy removes the uterus and one ovary, causing permanent infertility despite the tumor being localized. - This is overly aggressive for an adolescent with stage 1a disease; the uninvolved uterus should be preserved to maintain reproductive potential. Bilateral salpingo-oophorectomy alone - Bilateral salpingo-oophorectomy removes both ovaries and fallopian tubes, causing sterility and premature menopause in an adolescent. - This is unnecessary for unilateral localized disease, because the opposite ovary can be preserved while treating the involved ovary. Chemotherapy - Chemotherapy is effective against dysgerminoma but is generally reserved for advanced, recurrent, or residual disease rather than completely resected stage 1a disease. - When complete surgical resection is achievable, chemotherapy is not the primary initial treatment and would expose the patient to avoidable toxicity.

Flashcards: Chemotherapy in Gynecologic Oncology

  1. 1. For treatment of low risk GTN, methotrexate with is recommended

    Show answer

    folinic acid

  2. 2. Treatment for primary invasive cervical carcinoma: IA1: Type _____ Hysterectomy IA2: Type II (Modified Radical/ Wertheim) Hysterectomy IB1-IB2, and IIA1: Type _____ Hysterectomy IB3, IIA2 onwards: _____

    Show answer

    I (Simple) · III (Radical/Meigs-Wertheim) · Chemoradiation

  3. 3. Stage III vulvar cancers can be treated by for local recurrence

    Show answer

    Chemoradiotherapy

  4. 4. Sentinel lymph node biopsy is most useful in  carcinoma among gynecological malignancies.

    Show answer

    vulval

  5. 5. Uterine malignancy is a(n) contraindication to uterine artery embolisation

    Show answer

    absolute

  6. 6. Stage IV vulval cancers can be treated by as mainstay treatment along with local excision on residual tumor

    Show answer

    Primary chemoradiation (chemoradiotherapy)

  7. 7. Cytobrush is used to take samples from the _____

    Show answer

    endocervix

  8. 8. The given CT abdomen suggestive of hydronephrosis is suggestive of Stage _____ Cervical cancer

    Show answer

    IIIB

  9. 9. Choriocarcinoma in females may arise as a complication of _____ or as a spontaneous _____

    Show answer

    gestation · germ cell tumor

  10. 10. The next step in managing a patient who has HSIL on her pap smear is to perform a _____ and directed _____

    Show answer

    colposcopy · cervical biopsies

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF